Brokerages set USD 12.00 target for Replimune stock

Published on 10/15/2026 at 21:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Next earnings are estimated for November 5, 2026. Replimune stock costs EUR 10.56 on October 15, 2026, up 3.78 percent on Nasdaq.

Investor numbers for Replimune

MarketBeat reported a USD 12.00 average target from ten ratings firms on October 13, 2026, 1.52 percent above the Nasdaq price.
Replimune's next estimated earnings date is November 5, 2026.
Replimune stock costs EUR 10.56 at Lang & Schwarz on October 15, 2026 at 9:42 p.m. CEST, up 3.78 percent on Nasdaq.
Replimune had a USD 1.1 billion market capitalization and a negative P/E ratio of -3.76 on October 15, 2026.

REPL, US76029N1063, Illustration mit AI erstellt.

Replimune Group stock has a USD 12.00 average analyst target, which stood 1.52 percent above the company's USD 11.82 Nasdaq price on October 15, 2026. MarketBeat said on October 13, 2026 that ten ratings firms held a Moderate Buy consensus, with six buy ratings, one strong-buy rating, one hold rating and two sell ratings. The target calculation uses the Nasdaq price and the USD target in the same currency.

At Lang & Schwarz, Replimune stock was trading at EUR 10.56 on October 15, 2026 at 9:42 p.m. CEST. The Nasdaq quote was USD 11.82 at 3:48 p.m. ET, up 3.78 percent on the day, while the trading volume was 1,175,001 shares against an average of 4,102,926.

Price position and yearly range

The Nasdaq price sat between a 52-week low of USD 1.50 and a high of USD 16.33 on October 15, 2026. That places the stock 27.63 percent below its high and 688.00 percent above its low. The 50-day moving average was USD 13.88 and the 200-day moving average was USD 9.64 on October 13, 2026, according to MarketBeat.

Valuation and November date

Replimune had a USD 1.1 billion market capitalization and a negative P/E ratio of -3.76 on October 15, 2026. The company pays no dividend, and its dividend yield was 0.00 percent. MarketBeat estimates the next earnings announcement for November 5, 2026, before the Nasdaq open. Its forecast calls for a loss of USD 0.7840 per share and revenue of USD 1.00 million in the second quarter of fiscal year 2027.

The IR page lists Replimune's October 1, 2026 announcement that TUDRIQEV became available in the United States for advanced melanoma. The company's platform is built around engineered HSV-1 viruses intended to destroy tumors and stimulate a systemic immune response, according to Replimune.

Comparison with peers

Replimune (Nasdaq, USD): plus 3.78 percent, P/E -3.76, market capitalization USD 1.1 billion
Iovance Biotherapeutics (Nasdaq, USD): plus 2.96 percent, P/E -20.05, market capitalization USD 6.6 billion
CG Oncology (Nasdaq, USD): minus 0.21 percent, P/E -22.85, market capitalization USD 5.5 billion

Trading position

The combination of a USD 12.00 consensus target and a November 5 reporting date gives the stock two near-term reference points. The current Nasdaq price remains below its 50-day average but above its 200-day average, while the biotechnology peers show different daily directions and larger market values.

Replimune stock was trading at EUR 10.56 at Lang & Schwarz on October 15, 2026 at 9:42 p.m. CEST, up 3.78 percent on Nasdaq.

The further course of trading is shown by the continuously updated real-time quote of Replimune stock.